Table 4 Il28B favourable genotype prevalence reported in different countries
IL28B SNP | Uninfected population % (n) | HCV-infected population % (n) | Country | Year of publication |
|---|---|---|---|---|
Rs12979860; CC | ||||
44.7 (378) | 45.6 (283) | Spain | 2010 [42] | |
45.1 (122) | 26.9 (108) | Egypt | 2015 [43] | |
44.6 (92) | 32.1 (136) | Turkey | 2015 [41] | |
43.7 (142) | 38.0 (921) – 42.0 (100) | Iran | ||
86.9 (320) | 88.6 (297) | China | 2015 [51] | |
ND | 24.1 (83) | Mexico | 2012 [25] | |
35.7 (185) | ND | Bolivia | 2014 [26] | |
38.1 (76) | ND | Peru | 2014 [26] | |
38.8 (98) | ND | Paraguay | 2014 [26] | |
37.0 (405) | 20.2 (99) | Chile | ||
51.6 (991) | 18.4 (102) | Argentina | ||
47.4 (190) | 24.0 (221) – 30.9 (175) | Brazil | ||
45.6 (92) | 29.5 (78) | Uruguay | This study | |
rs8099917; TT | ||||
64.1 (142) | 58.3 (921) | Iran | 2012 [49] | |
88.7 (320) | 89.6 (297) | China | 2015 [51] | |
89.3 (197) | 81.0 (400) | Taiwan | 2016 [45] | |
ND | 27.5 (80) | Mexico | 2012 [25] | |
46.9 (405) | 29.3 (99) | Chile | ||
ND | 40.2 (102) | Argentina | 2011 [29] | |
67.8 (199) | 54.2 (177) – 63.1 (222) | Brazil | ||
60.9 (92) | 57.7 (78) | Uruguay | This study | |